HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ozen Oz Gul Selected Research

Receptor for Advanced Glycation End Products

6/2009Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ozen Oz Gul Research Topics

Disease

3Diabetes Mellitus
03/2019 - 12/2014
2Atherosclerosis
10/2018 - 01/2018
1Congenital Adrenal Hyperplasia (Hyperplasia, Congenital Adrenal)
04/2024
1Neoplasm Metastasis (Metastasis)
04/2024
1Diabetic Neuropathies (Diabetic Neuropathy)
01/2022
1Dyslipidemias (Dyslipidemia)
01/2022
1COVID-19
01/2022
1Hypertension (High Blood Pressure)
01/2022
1Diabetes Complications
01/2022
1Adrenocortical Carcinoma
09/2020
1Adenoma (Adenomas)
09/2020
1Carcinoma (Carcinomatosis)
09/2020
1Hypercalcemia (Milk Alkali Syndrome)
07/2020
1Hyperparathyroidism
07/2020
1Parathyroid Neoplasms (Parathyroid Neoplasm)
07/2020
1Hyperinsulinism (Hyperinsulinemia)
01/2020
1Insulinoma
01/2020
1Overweight
03/2019
1Weight Loss (Weight Reduction)
03/2019
1Hyperlipidemias (Hyperlipidemia)
03/2019
1Hypoglycemia (Reactive Hypoglycemia)
01/2019
1Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
10/2018
1Inborn Genetic Diseases (Disease, Hereditary)
10/2018
1Homozygous Familial Hypercholesterolemia
01/2018
1Coronary Disease (Coronary Heart Disease)
01/2018
1Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell)
01/2017
1Insulin Resistance
10/2015
1Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
10/2015
1Morbid Obesity
10/2015
1Body Weight (Weight, Body)
12/2014
1Neoplasms (Cancer)
10/2014
1Type 2 Diabetes Mellitus (MODY)
10/2009
1Metabolic Syndrome (Dysmetabolic Syndrome X)
06/2009
1Non-alcoholic Fatty Liver Disease
06/2009

Drug/Important Bio-Agent (IBA)

3Glucose (Dextrose)FDA LinkGeneric
01/2020 - 01/2019
1SteroidsIBA
04/2024
1trans-crotonin (CTN)IBA
04/2024
14-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
01/2022
1CarbohydratesIBA
01/2022
1Biomarkers (Surrogate Marker)IBA
09/2020
1DiureticsIBA
07/2020
1DenosumabFDA Link
07/2020
1CalciumIBA
07/2020
1Diphosphonates (Bisphosphonates)IBA
07/2020
1Parathyroid Hormone (Parathormone)IBA
07/2020
1Calcimimetic AgentsIBA
07/2020
1Hypoglycemic Agents (Hypoglycemics)IBA
01/2020
1Sodium-Glucose Transport ProteinsIBA
03/2019
1LipidsIBA
03/2019
1dapagliflozinIBA
03/2019
1Sodium-Glucose Transporter 2 InhibitorsIBA
01/2019
1Insulin (Novolin)FDA Link
01/2019
1CholesterolIBA
10/2018
1oxidized low density lipoproteinIBA
01/2018
1LDL CholesterolIBA
01/2018
1ResistinIBA
10/2015
1Nicotinamide PhosphoribosyltransferaseIBA
10/2015
1Blood Glucose (Blood Sugar)IBA
12/2014
1Insulin-Like Growth Factor I (IGF-1)IBA
10/2014
1Rosiglitazone (Avandia)FDA Link
10/2009
1Matrix Metalloproteinases (MMPs)IBA
10/2009
1Metformin (Glucophage)FDA LinkGeneric
10/2009
1Monocyte Chemoattractant ProteinsIBA
10/2009
1Receptor for Advanced Glycation End ProductsIBA
06/2009

Therapy/Procedure

3Glycemic Control
03/2019 - 12/2014
2Therapeutics
07/2020 - 03/2019
1Blood Component Removal (Apheresis)
01/2018
1Thyroidectomy
01/2017
1Diabetic Diet
12/2014